TLDR
- Mira Pharmaceuticals stock jumped 70% after-hours following preclinical data showing oral drug Mira-55 outperformed injected morphine in pain relief and inflammation reduction.
- The study found Mira-55 fully normalized pain thresholds and reduced swelling through CB2 receptor action, while morphine only partially reduced inflammation.
- The non-psychotropic marijuana analog targets the $70 billion non-opioid pain market and will support an upcoming IND application for chronic inflammatory pain.
- Retail investor sentiment hit “extremely bullish” with message volume spiking 7,000% on Stocktwits as traders called it a potential blockbuster drug.
- MIRA stock has risen 16% year-to-date in 2025, with shares closing at $1.32 before the after-hours surge to $2.23.
Mira Pharmaceuticals stock surged 70% in after-hours trading Wednesday after releasing preclinical data for its lead drug candidate. The company announced that oral Mira-55 outperformed injected morphine in treating chronic inflammatory pain in animal models.
MIRA Pharmaceuticals, Inc. (MIRA)Shares closed regular trading at $1.32, up 0.76% for the day. After the announcement, the stock jumped to $2.23 in extended trading.
The preclinical study tested Mira-55 against morphine using animal models of chronic inflammatory pain. Researchers used formalin injections in rat paws, a standard test for pain research.
Mira-55 restored pain thresholds to baseline levels. The drug also prevented swelling and inflammation that typically comes with this type of pain.
Morphine relieved some pain but only partially reduced swelling. The opioid worked indirectly through central nervous system effects.
Dual Action Mechanism
The company said this marks the first time they directly measured inflammation alongside pain in the Mira-55 program. The dual action sets the drug apart from traditional opioid treatments.
Mira-55 works through CB2 receptor-mediated mechanisms. These receptors are part of the endocannabinoid system linked to anti-inflammatory and pain-relief pathways.
The drug is a non-psychotropic marijuana analog. It avoids the psychoactive effects of THC by targeting CB2 receptors instead of CB1 receptors.
The company is targeting the $70 billion non-opioid pain market. These findings will support Mira’s planned Investigational New Drug application for chronic inflammatory pain.
Mira plans to file an IND with the FDA to begin human trials. The company aims to move into Phase 1 clinical trials as soon as possible.
Retail Investor Response
Mira’s stock has risen 16% so far in 2025. The 52-week trading range before this news was $0.73 to $2.56.
The company’s market cap was about $25 million at Wednesday’s close. At the elevated after-hours price, valuation reached roughly $50 million.
Mira is also developing Ketamir-2, a ketamine analog for neuropathic pain. The drug received FDA IND clearance earlier this year for U.S. clinical trials.
The company reported favorable Phase 1 results for Ketamir-2 in September. The single-ascending-dose study showed the drug was safe and well-tolerated with no serious side effects.
Mira recently completed an acquisition of SKNY Pharmaceuticals. The deal added SKNY-1, a compound for obesity and nicotine addiction, to the pipeline.
The acquisition brought $5 million in cash and assets to Mira’s balance sheet. SKNY-1 caused 30% weight reduction in preclinical models while reducing nicotine cravings.
Mira is scheduled to report third-quarter financial results on November 11. The company had no revenue in Q2 and posted a net loss of $0.09 per share.
The post Mira Pharmaceuticals (MIRA) Stock Rockets After Pain Drug Tops Morphine in Trials appeared first on Blockonomi.
Source: https://blockonomi.com/mira-pharmaceuticals-mira-stock-rockets-after-pain-drug-tops-morphine-in-trials/
